GLIS2 and acute myeloid leukemia: In addition to samples expressing NUP98::KDM5A and NUP98::NSD1 (n = 4, each), we included samples from other pediatric AML patients (n = 7) with different oncogenic driver mutations (KMT2A::MLLT3, CBFB::MYH11, CBFA2T3::GLIS2, and normal karyotype) (Supplementary Data 1).